The global treatment dementia syndrome and movement disorders market has been rising significantly in recent years. In 2014, the market stood at a valuation of US$12.8 bn. Expanding at a CAGR of 8.60% during the period from 2014 to 2020, it is anticipated to reach a value of US$21.1 bn by the end of 2020.
Dementia is one of the major reasons of disability among elderly people. The accelerating geriatric population across the world is driving the global market for treatment of dementia syndrome and movement disorders significantly. However, the strict rules and regulations regarding the treatment of dementia syndrome and movement disorders, coupled with the elongated approval period for the drugs required in these treatments, are likely to hamper the market in the coming years.
North America Leads Global Market
The global market for treatment of dementia syndrome and movement disorders is segmented into North America, Asia, Europe, and the Rest of the World. North America is the biggest treatment market for dementia syndrome and movement disorders at present.
The increasing prevalence of neurodegenerative disorders has driven the treatment market for dementia syndrome and movement disorders greatly in North America over the last few years. By the end of 2020, this regional market is expected to reach a value of US$9 bn. The rising awareness regarding dementia syndrome and movement disorders is likely to propel this regional market significantly in the coming years.
Asia to Report Highest Growth in Global Market
The Asia market for the treatment of dementia syndrome and movement disorders is projected to report the highest growth in the global market over the next few years due to the huge population base and the widening penetration of health insurance in this region. Analyst project this market to arrive at an estimated value of US$3.8 bn by the end of 2017.
The Europe market for the treatment of dementia syndrome and movement disorders has been rising at an impressive rate over the past few years. It is driven by the increasing incidence of mental disorders in this region. The numerous awareness programs initiated by several public and private health institutions in order to curb dementia and movement disorders are likely to increase the demand for dementia syndrome and movement disorders treatments in the region in the near future.
Alzheimer’s Treatment Segment to be worth US$8.2 bn by 2020
Alzheimer’s disease, frontotemporal dementia (FTD), and Lewy body dementia (LBD) are the major types of dementia. Among these, the Alzheimer’s treatment market is likely to expand at a CAGR of 9.50% between 2014 and 2020 and reach a value of US$8.2 mn by the end of 2020 from a total value of US$4.7 bn in 2014.
Sanofi, F. Hoffmann-La Roche Ltd., Valeant Pharmaceuticals Int. Inc., Novartis AG, Baxter, Merck & Co. Inc., Pfizer Inc., Abbott Laboratories Inc., AstraZeneca GmbH, and Bristol-Myers Squibb Co. are the key players operating in the global treatment market for dementia syndrome and movement disorders.
Browse Full Global Treatment for Syndromes of Dementia and Movement Disorders Market Research Report With Complete TOC @ https://www.persistencemarketresearch.com/market-research/treatment-syndromes-dementia-movement-disorders-market.asp